Mankind Pharma to Host Investor Call on Feb 3 for Q3 & 9M FY26 Results
Mankind Pharma Limited will host an investor conference call on February 3, 2026, at 6:00 PM IST to discuss Q3 and 9M FY26 results. Key management personnel, including the MD and CEO, will participate. Dial-in details and pre-registration are available.
This is a standard procedural announcement for an upcoming investor call. It does not contain new financial information or strategic decisions that would significantly impact the company's stock price or operations.
The announcement is a routine intimation of a scheduled investor call and does not contain any financial results or specific business updates that would indicate a positive or negative sentiment.
Mankind Pharma Limited has announced that it will host an Investor Conference Call on Tuesday, February 3, 2026, at 06:00 PM IST. The call is scheduled to discuss the company's business performance and results for the third quarter (Q3) and the first nine months (9M) of the financial year 2026 (FY26).
The management team that will represent the company includes Mr. Rajeev Juneja (Vice Chairman & Managing Director), Mr. Sheetal Arora (Chief Executive Officer & Whole Time Director), Mr. Arjun Juneja (Chief Operating Officer), Mr. Sudipta Roy (Senior President – Sales & Marketing), Mr. Ashutosh Dhawan (Global Chief Financial Officer), Mr. Prakash Agarwal (President – Strategy), and Mr. Abhishek Agarwal (Head - Investor Relations & AVP - Strategy).
Participants can dial in using the provided universal dial-in numbers for India and international toll-free numbers for countries including the USA, UK, Singapore, and Hong Kong. The company also offers a pre-registration option to streamline the joining process. The announcement was made by Mr. Hitesh Kumar Jain, Company Secretary & Compliance Officer.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.